Sonendo Raises $63 Million Through Strategic Private Investment Round

Dental technology innovator Sonendo has successfully completed a significant capital injection, drawing $63 million in gross proceeds through a private investment initiative. The financing round, structured around common stock and pre-funded warrant offerings, attracted participation from an impressive roster of institutional investors including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, ArrowMark Partners, Driehaus Capital Management, and JMR Capital.

Strengthening Financial Position and Growth Strategy

The fresh capital infusion positions Sonendo to accelerate its commercialization efforts while expanding its product ecosystem. According to Bjarne Bergheim, the company’s President and CEO, this financing represents a pivotal moment for the organization. “This capital round meaningfully improves our financial foundation and empowers us to further advance patient care while expanding our portfolio of innovative solutions centered on our core mission of Saving Teeth. Improving Lives™,” Bergheim stated.

The net proceeds will be deployed strategically across multiple initiatives: scaling current commercialization activities, broadening the company’s product offerings, and providing operational flexibility for general corporate needs.

Investment Details and Structure

The financing mechanism involved converting capital into 23,045,536 shares of common stock at $0.95 per share, alongside pre-funded warrants authorizing an additional 43,315,846 shares at $0.949 per warrant. These pre-funded warrants carry an exercise price of merely $0.001 per share, with immediate exercisability until fully exercised. The transaction was facilitated by BofA Securities and Stifel as co-lead placement agents, with anticipated closure on or around September 27, 2022.

Investor Confidence in GentleWave Technology

The investor syndicate demonstrated strong conviction in Sonendo’s technological platform. Matt Arens, founder and CEO of First Light Asset Management, highlighted the appeal: “Our comprehensive due diligence has reinforced our belief in the transformative potential of Sonendo’s advanced technology for reshaping the dental industry, particularly as practitioners recognize its capacity to meaningfully enhance their operational efficiency and clinical outcomes.”

Arens emphasized the compelling value proposition: “Beyond innovative technology, Sonendo combines experienced leadership with a scalable operational framework. With this financing secured, we anticipate Sonendo entering an exciting growth trajectory marked by margin expansion and substantial stakeholder value creation.”

Similarly, Efrem Kamen of Pura Vida Investments expressed enthusiasm: “This investment reinforces our commitment to advancing Sonendo’s mission of delivering superior clinical performance and enriching the endodontic treatment experience for patients. We anticipate supporting the company as it navigates the next chapter of expansion and technological advancement.”

GentleWave System: Technology and Clinical Advantage

At the heart of Sonendo’s proposition lies the GentleWave System, a proprietary treatment platform addressing tooth decay—the most prevalent chronic disease globally. The technology employs an integrated approach combining fluid optimization, broad-spectrum acoustic energy, and sophisticated fluid dynamics to clean and disinfect the intricate root canal architecture with minimal structural invasion.

Compared to conventional endodontic approaches, this system delivers measurable advantages: enhanced cleaning effectiveness regardless of canal complexity, accelerated healing trajectories, and substantially reduced post-operative discomfort. For dental practitioners, the GentleWave ecosystem improves workflow efficiency and practice economics while offering patients a more conservative and comfortable alternative to traditional interventions.

Sonendo’s technological ecosystem extends through its ownership of TDO Software, a comprehensive endodontic practice management platform that streamlines workflows through integrated practice administration, imaging capabilities, referral documentation, and CBCT functionality, with direct system connectivity to the GentleWave apparatus.

Regulatory Framework and Future Outlook

The securities issued through this private placement will undergo SEC registration to enable future resale, though current offerings remain restricted pending registration effectiveness or applicable exemptions under securities legislation. The transaction structure reflects standard institutional investment frameworks while positioning Sonendo for the next phase of market expansion and clinical adoption.